Jacob Chacko - 15 Dec 2024 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
15 Dec 2024
Net transactions value
-$204,214
Form type
4
Filing time
17 Dec 2024, 17:21:01 UTC
Previous filing
23 May 2024
Next filing
03 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Options Exercise $0 +67,000 +9.1% $0.000000 803,308 15 Dec 2024 Direct F1, F2
transaction ORIC Common Stock Sale $204,214 -24,660 -3.1% $8.28 778,648 16 Dec 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Restricted Stock Unit Options Exercise $0 -16,667 -100% $0.000000 0 15 Dec 2024 Common Stock 16,667 Direct F1, F5
transaction ORIC Restricted Stock Unit Options Exercise $0 -22,000 -50% $0.000000 22,000 15 Dec 2024 Common Stock 22,000 Direct F1, F6
transaction ORIC Restricted Stock Unit Options Exercise $0 -28,333 -33% $0.000000 56,667 15 Dec 2024 Common Stock 28,333 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
F2 Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
F3 Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
F4 Represents the weighted average share price of an aggregate total of 24,660 shares sold in the price range of $8.27 to $8.39 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.
F6 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
F7 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.